Addex Pharmaceuticals First Half Financial Results on July 27

Addex Pharmaceuticals /
Addex Pharmaceuticals First Half Financial Results on July 27
. Verarbeitet und übermittelt durch Thomson Reuters ONE.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich. Geneva, Switzerland, 20 July 2011 - Allosteric modulation company Addex
Pharmaceuticals Ltd. (SIX:ADXN) will discuss its financial results for the first
half of 2011 and update the status of key products in development during a
teleconference and webcast for investors, analysts and the media on Wednesday,
July 27 at 16:00 CET (15:00 BST/10:00 EST).Conference Call & WebcastTitle:     Addex First Half 2011 Financial Results Conference Call
Date:    27 July 2011
Time:    16:00 CEST (15:00 BST/10:00 EST).Dial-in numbers:
+41 91 610 56 00  (Europe)
+44 203 059  58 62(UK)
+1 866 291 4166   (USA)A live webcast and slides, as well as the webcast replay and transcript, will be
available at www.addexpharma.com.Addex Pharmaceuticals (www.addexpharma.com) discovers and develops allosteric
modulators for human health. The company uses its proprietary small molecule
discovery platform to target cell surface receptors that are recognized as
having therapeutic potential for treating diseases of the central nervous
system, metabolic disorders or inflammation. Two Phase IIa clinical trials are
ongoing for two lead products: dipraglurant (ADX48621) and ADX71149.
Dipraglurant is an mGluR5 negative allosteric modulator (NAM), which is being
tested in Parkinson's disease levodopa-induced dyskinesia (PD-LID). ADX71149, an
mGluR2 positive allosteric modulator (PAM), is being tested for treatment of
schizophrenia by our partner Ortho-McNeil-Janssen Pharmaceuticals Inc. In
addition, Merck & Co., Inc. has licensed rights to two preclinical programs:
mGluR4 PAM for Parkinson's disease and mGluR5 PAM for schizophrenia. Unpartnered
products in preclinical testing include: follicle stimulating hormone receptor
(FSHR) NAM, with potential for endometriosis and benign prostatic hyperplasia;
mGluR2 NAM for Alzheimer's disease; and GABA-BR PAM with potential for chronic
pain, Fragile X syndrome, urinary incontinence and gastroesophageal reflux
disease. Preclinical diabetes and inflammation discovery programs include GLP-
1R PAM, IL-1R1 NAM, and TNFR1 NAM.Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11 Direct
+41 22 884 15 55 General
chris.maggos(at)addexpharma.comDisclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5, mGluR7 or other therapeutic targets to be materially different from any
future results, performance or achievements expressed or implied by such
statements. There can be no guarantee that allosteric modulators of mGluR2,
mGluR4, mGluR5, mGluR7 will be approved for sale in any market or by any
regulatory authority. Nor can there be any guarantee that allosteric modulators
of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets will achieve any
particular levels of revenue (if any) in the future. In particular, management's
expectations regarding  allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7
or other therapeutic targets could be affected by, among other things,
unexpected actions by our partners, unexpected regulatory actions or delays or
government regulation generally; unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of existing
clinical data; competition in general; government, industry and general public
pricing pressures; the company's ability to obtain or maintain patent or other
proprietary intellectual property protection. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Addex Pharmaceuticals Ltd is providing the information in this
press release as of this date and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of
new information, future events or otherwise, except as may be required by
applicable laws.
--- Ende der Mitteilung --- Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva SchweizISIN: CH0029850754;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Addex Pharmaceuticals via Thomson Reuters ONE[HUG#1532403]